表紙
市場調查報告書

精準醫學的全球市場:成長,趨勢,及預測(2019年∼2024年)

Precision Medicine Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 390725
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
Back to Top
精準醫學的全球市場:成長,趨勢,及預測(2019年∼2024年) Precision Medicine Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年12月01日內容資訊: 英文 112 Pages
簡介

全球精準醫學市場在2018年估算為485億5,410萬美金。該市場在2019年∼2024年間,預測將以9.7%的年複合成長率成長,2024年達到845億9,021萬美元的規模。線上的共同論壇的增加,遺傳基因特徵帳單的配合措施增加,及癌症生物學的進步等,為該市場的成長要素。

本報告提供全球精密醫療市場的相關調查,市場機會和課題,成長及阻礙因素,各技術、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
    • 線上合作論壇的增加
    • 遺傳基因特徵帳單的配合增加
    • 癌症生物學的進步
  • 阻礙因素
    • 資料共享的危險
    • 從治療為基礎轉移到預防醫療保健
    • FDA的藥物療法核准率的減少趨勢
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品及服務的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各技術
    • 巨量資料分析
    • 生物資訊學
    • 遺傳基因排列
    • 藥物研發
    • 搭配診斷
    • 其他
  • 各用途
    • 腫瘤
    • CNS
    • 免疫
    • 呼吸系統
    • 其他的用途
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Biocrates Life Sciences AG
    • Nanostring Technologies
    • Intomics
    • Pfizer Inc.
    • Eagle Genomics Ltd
    • Teva Pharmaceutical Industries Ltd
    • Laboratory Corporation Of America Holdings
    • Medtronic
    • Novartis AG
    • Qiagen NV
    • Quest Diagnostics Incorporated

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52313

Market Overview

The global precision medicine market was valued at USD 48,554.1 million in 2018, and is estimated to be valued at USD 84,590.21 million in 2024, witnessing a CAGR of 9.7%. The key factors propelling the growth of this market are increasing online collaborative forums, increasing efforts to characterize genes, and advancements in cancer biology. The fundamental concept of precision medicine is to understand the genetic makeup and difference at a population level, and further at an individual level, in order to customize a drug that targets a particular gene type. Hence, sequencing or characterizing genes is the most important method to gain information about genes and their possible mutations.

The functional characterization of identified genomic mutations, coupled with comprehensive clinical data available in electronic health records, has the potential to provide compelling evidence to implicate novel disease and/or drug-associated mutations in phenotypically well-characterized patients. There have been increasing efforts made by both the government and private players to establish databases that contain information of characterized genes of a large population. Some countries are establishing a national repository of genetic information to accelerate the research in precision medicine. Methods, such as meta-analysis, transcriptome data analysis, and RNA-seq data analysis, are employed to characterize genes, generally.

Scope of the Report

Precision medicine, a combination of molecular biology techniques and systems biology, is an emerging approach for disease treatment and prevention. The market growth for this approach is gaining momentum, as it takes into account individual variability in genes, environment, and lifestyle, for each person, while developing drugs and vaccines.

Key Market Trends

Oncology is Expected to hold the Highest Market Share in the Application Segment

In the application segment of the precision medicine market, oncology is believed to have the largest market size and is expected to witness a CAGR of 10.3%, during the forecast period.

Precision medicine applications are primarily directed toward better treatment against oncological diseases, with an estimated more than 30% market dominance over other segments. As per the data reported in clinicaltrials.gov, the United States and some European countries are the major hubs for conducting and recruiting patient pool for precision medicine applications in oncology, globally. The high support from the government through funding and rapid growth of genomic analysis are expected to augment the growth of the precision medicine market at a fast rate, over the forecast period.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America currently dominates the market for precision medicine, and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. Former President Barack Obama, in 2015, unveiled the Precision Medicine Initiative (PMI), a bold new enterprise to revolutionize medicine and generate the scientific evidence needed to move the concept of precision medicine into every-day clinical practice.

The Precision Medicine Initiative also includes ongoing efforts through the Department of Veteran's Affairs (VA), which has enrolled over 450,000 veterans in the Million Veteran Program (MVP), a participant-driven research cohort. The Food and Drug Administration (FDA), the Office of the National Coordinator for Health IT, and the Office for Civil Rights announced in February 2016 that they will build research and data capacity, technical tools, and policies to accelerate precision medicine, thereby, boosting the precision medicine market in the country.

Competitive Landscape

The precision medicine market is highly competitive and consists of several major players, along with a number of smaller companies. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies with affordable prices. Companies, like Medtronic PLC, Pfizer Inc., Novartis AG, Qiagen, and Teva Pharmaceuticals, hold substantial shares in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Online Collaborative Forums
    • 4.2.2 Increasing Efforts to Characterize Genes
    • 4.2.3 Advancement in Cancer Biology
  • 4.3 Market Restraints
    • 4.3.1 Perils of Data Sharing
    • 4.3.2 Shift From Treatment-based To Preventive Healthcare
    • 4.3.3 Declining Trends in FDA Pharmacotherapy Approval Rate
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Technology
    • 5.1.1 Big Data Analytics
    • 5.1.2 Bioinformatics
    • 5.1.3 Gene Sequencing
    • 5.1.4 Drug Discovery
    • 5.1.5 Companion Diagnostics
    • 5.1.6 Other Technologies
  • 5.2 By Application
    • 5.2.1 Oncology
    • 5.2.2 CNS
    • 5.2.3 Immunology
    • 5.2.4 Respiratory
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Biocrates Life Sciences AG
    • 6.1.2 Nanostring Technologies
    • 6.1.3 Intomics
    • 6.1.4 Pfizer Inc.
    • 6.1.5 Eagle Genomics Ltd
    • 6.1.6 Teva Pharmaceutical Industries Ltd
    • 6.1.7 Laboratory Corporation Of America Holdings
    • 6.1.8 Medtronic
    • 6.1.9 Novartis AG
    • 6.1.10 Qiagen NV
    • 6.1.11 Quest Diagnostics Incorporated

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top